@carmecortina.bsky.social
Reposted
1/17 🧵
🙌Thrilled to share our first hard-core immunology paper out today in Nature Genetics! 👇
➡️We unravel how TGFβ suppresses the innate and adaptive immune system in microsatellite stable colorectal cancer (MSS CRC).
Very proud of the team and efforts behind it.
www.nature.com/articles/s41...
🙌Thrilled to share our first hard-core immunology paper out today in Nature Genetics! 👇
➡️We unravel how TGFβ suppresses the innate and adaptive immune system in microsatellite stable colorectal cancer (MSS CRC).
Very proud of the team and efforts behind it.
www.nature.com/articles/s41...
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages - Nature Genetics
Targeting TGFBR1 in transplantable mouse colorectal tumor organoids improves response to anti-PD-L1 therapy. Mechanistically, TGF-β abrogates clonal expansion of T effector and memory phenotypes and i...
www.nature.com
November 7, 2025 at 12:30 PM
1/17 🧵
🙌Thrilled to share our first hard-core immunology paper out today in Nature Genetics! 👇
➡️We unravel how TGFβ suppresses the innate and adaptive immune system in microsatellite stable colorectal cancer (MSS CRC).
Very proud of the team and efforts behind it.
www.nature.com/articles/s41...
🙌Thrilled to share our first hard-core immunology paper out today in Nature Genetics! 👇
➡️We unravel how TGFβ suppresses the innate and adaptive immune system in microsatellite stable colorectal cancer (MSS CRC).
Very proud of the team and efforts behind it.
www.nature.com/articles/s41...
Reposted
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
October 24, 2025 at 6:47 AM
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
Reposted
🧵1/17
📣Thrilled to share our latest study just out in Cancer Discovery!
➡️
aacrjournals.org/cancerdiscov...
📣Thrilled to share our latest study just out in Cancer Discovery!
➡️
aacrjournals.org/cancerdiscov...
A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer
Abstract. Inhibitors of the oncogene KRAS hold promise for treating metastatic CRC (mCRC). Here we show that a selective, covalent small molecule inhibitor of the active (ON) conformation of RAS-G12D,...
aacrjournals.org
October 23, 2025 at 6:07 PM
🧵1/17
📣Thrilled to share our latest study just out in Cancer Discovery!
➡️
aacrjournals.org/cancerdiscov...
📣Thrilled to share our latest study just out in Cancer Discovery!
➡️
aacrjournals.org/cancerdiscov...
Reposted
🚨New advances in colorectal cancer!
Why do some colorectal cancers resist KRAS-targeted therapies?
🔝Our new study in Cancer Discovery discovery reveals the answer, and opens the door to more effective treatments. By @mamartirenom.bsky.social (CNAG) & @irbbarcelona.org
🔗 www.cnag.eu/news/study-r...
Why do some colorectal cancers resist KRAS-targeted therapies?
🔝Our new study in Cancer Discovery discovery reveals the answer, and opens the door to more effective treatments. By @mamartirenom.bsky.social (CNAG) & @irbbarcelona.org
🔗 www.cnag.eu/news/study-r...
October 23, 2025 at 2:01 PM
🚨New advances in colorectal cancer!
Why do some colorectal cancers resist KRAS-targeted therapies?
🔝Our new study in Cancer Discovery discovery reveals the answer, and opens the door to more effective treatments. By @mamartirenom.bsky.social (CNAG) & @irbbarcelona.org
🔗 www.cnag.eu/news/study-r...
Why do some colorectal cancers resist KRAS-targeted therapies?
🔝Our new study in Cancer Discovery discovery reveals the answer, and opens the door to more effective treatments. By @mamartirenom.bsky.social (CNAG) & @irbbarcelona.org
🔗 www.cnag.eu/news/study-r...
Reposted
A study published in #CancerDiscovery reveals why some colorectal cancers withstand pharmacological inhibition of #KRAS oncogene activity.
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
October 23, 2025 at 2:03 PM
A study published in #CancerDiscovery reveals why some colorectal cancers withstand pharmacological inhibition of #KRAS oncogene activity.
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪